Compartment Syndromes

MONTREAL, Sept. 12, 2023 /PRNewswire/ - MY01, Inc., a pioneering company dedicated to revolutionizing the diagnosis of compartment syndrome, today announced it has achieved a milestone of serving 1000 patients at risk for this severe complication. This achievement underscores MY01's commitment to providing reliable, real-time pressure measurements that empower healthcare professionals in making critical diagnostic decisions. Compartment syndrome, a limb-threatening condition often resulting from trauma, has long relied on subjective assessments for diagnosis. MY01's easy to use device, incorporating advanced Microelectromechanical Systems (MEMS) technology, introduces an objective and efficient approach to diagnosis. The device continuously monitors intracompartmental pressure, aiding in early and accurate diagnosis, which is vital to improve patient outcomes. Charles Allan, CEO of MY01, commented, "Crossing this milestone is a testament to our dedication to transforming patient care. We're proud that MY01 is rapidly becoming the gold standard for managing compartment syndrome. We're not just delivering devices; we're delivering insights that make a tangible difference in the lives of patients and healthcare professionals alike." The success stories stemming from MY01's devices highlight their vital role in enhancing clinical assessments and augmenting healthcare collaborations. With each device utilized, MY01 is progressively shaping a future where actionable data at the bedside leads to more effective patient care. About MY01, Inc. MY01, Inc. is a privately-held commercial stage medical technology company on a mission to empower healthcare professionals with objective data to aid in the diagnosis of compartment syndrome, thereby improving patient outcomes. MY01 believes that incorporating actionable, quantitative data at the bedside can augment clinical assessments and provide more effective care. Since its establishment in 2015, MY01, Inc., headquartered in Montreal, Quebec, has leveraged its expertise in microsensing technology to provide innovative diagnostic solutions. View original content to download multimedia: SOURCE MY01, Inc.

Modeled in part after National Transportation Safety Board, proposed entity would focus on preventing patient injury and harm NEWPORT NEWS, Va., Aug. 2, 2023 /PRNewswire/ -- ivWatch, LLC, the IV safety company, today announced that it has joined the National Patient Safety Board (NPSB) Advocacy Coalition. The proposed NPSB would model the efforts of the National Transportation Safety Board (NTSB) and Commercial Aviation Safety Team (CAST) in the healthcare space and would complement existing agencies in monitoring and anticipating patient safety events. Continue Reading ivWatch patient monitoring system for IV infiltrations and extravasations. ivWatch's goal to promote IV safety across all healthcare environments via its proprietary patient monitoring technology aligns directly with the NPSB's initiative to help protect patients from unpredictable IV complications, among other scenarios, with early IV infiltration and extravasation detection. "The alarming escalation of IV injury in the U.S. is a perfect case study for why a National Patient Safety Board is imperative right now. We are very excited to join the NPSB Advocacy Coalition and further our mission toward standards of practice that will improve patient safety in hospitals – especially reducing the incidence of IV injury to zero," said Christine Hayden, RN, BSN, and Director of Business Development who will serve as ivWatch's representative on the coalition. Prior to the COVID-19 pandemic, medical errors were the third leading cause of death in the United States, with conservative estimates of more than 250,000 patients dying annually from preventable medical harm and costs of more than $17 billion to the U.S. healthcare system. Recent data has shown that patient safety worsened during the pandemic. "We have seen many valiant efforts to reduce the problem of preventable medical error, but most of these have relied on the frontline workforce to do the work or take extraordinary precautions," said Karen Wolk Feinstein, Ph.D., president and CEO of the Pittsburgh Regional Health Initiative and spokesperson for the NPSB Advocacy Coalition. "Innovative technology solutions are crucial to our mission to shift the burden away from frontline healthcare workers while exponentially increasing patient safety across the U.S." ivWatch CEO Gary Warren, whose commentary on the formation of an NPSB is included in this month's issue of industry publication Healthcare Risk Management, notes: "The need for this is highlighted particularly in vascular access, our area of expertise. Over 80% of patients admitted to hospitals have this seemingly simple and common procedure. However, significant complication rates exist that lead to drug dosing errors, skin necrosis, scarring, compartment syndrome, and even amputation in severe instances. Ensuring the same level of safety for patients as we are entitled to in non-medical environments is an important and pressing issue, and we are looking forward to working closely with the National Patient Safety Board Advocacy Coalition in their efforts to do so," Warren says. About ivWatch, LLC ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, Instagram @ivWatchLLC and LinkedIn @ivWatch-LLC, or visit . SOURCE ivWatch, LLC

JACKSONVILLE, Fla., Aug. 2, 2023 /PRNewswire/ -- In the face of the ongoing supply issues affecting Intra-Abdominal Pressure (IAP) transducer kits, Sentinel Medical Technologies is stepping up to ensure that patient care remains uncompromised. The company's FDA-cleared product, TraumaGuard, is now readily available to fill the gap left by the shortage of CR BARD or Centurion IAP kits. Continue Reading TraumaGuard Continuous Intra-Abdominal Pressure Monitoring System IAP monitoring is a critical component of patient care in OR and ICU settings. It serves as a crucial guide for medical teams in assessing the risk of developing Intra-Abdominal Hypertension (IAH) and Abdominal Compartment Syndrome (ACS), conditions that can have severe consequences if not addressed promptly. Given the critical importance of IAP measurements, the ongoing shortage of transducer kits has created obstacles for healthcare providers, increasing the barriers in delivering essential, life-saving care. TraumaGuard offers a solution to this pressing issue. More than a product, TraumaGuard is a commitment to patient care. It provides continuous, hands-free monitoring of IAP, Core Body Temperature, and bladder drainage in critical care patients of all departments. Once administered, TraumaGuard can be left in place for 30 days, eliminating clinical staff burden and improving workflow. Moreover, TraumaGuard's unique technology is designed with patient safety in mind. It actively detects advancement toward Abdominal Compartment Syndrome (ACS), sending proactive alerts to both bedside and nurses' stations while automatically recording and storing measurements in the existing EMR database. This allows for timely interventions that can prevent the escalation of negative patient conditions. In addition to its clinical benefits, TraumaGuard also offers significant cost savings. When actively deployed, it reduces the overall cost of patient care while requiring no capital equipment and can be connected to existing bedside monitors. This makes TraumaGuard a cost-competitive and equivalent replacement to existing IAP devices. Patrick Beer, DO, Critical Care Surgery Specialist, Hurley Medical Center, commented on the situation: "The availability of TraumaGuard comes at a time when IAP transducer kits are currently unavailable or discontinued. This shortage has been a major challenge for OR and ICU teams, who rely on IAP monitoring to assess the risk of Intra-Abdominal Hypertension (IAH) and Abdominal Compartment Syndrome (ACS)." Sentinel Medical Technologies is committed to ensuring the availability of TraumaGuard now and in the future. The company understands the critical role that IAP monitoring plays in patient care and is dedicated to ensuring that healthcare providers have the tools they need to deliver the best possible outcomes. For more information about TraumaGuard, please visit About Sentinel Medical Technologies: Sentinel Medical Technologies is a focused-leader in health technology, committed to saving lives with pressure monitoring. Founded with the mission to advance the standard of care, Sentinel offers a growing suite of innovative pressure-based monitoring devices that cater to a variety of disease states. By unlocking the power of data at the point of care, Sentinel delivers value-based healthcare solutions that are simple, efficient, and cost-effective. Our cutting-edge technologies are designed to solve unmet clinical needs, instill technological confidence in the workflow, and improve patient outcomes. SOURCE Sentinel Medical Technologies